Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.

Guillaume LingasNadège NéantAlexandre GaymardDrifa BelhadiGilles PeytavinMaya HitesThérèse StaubRichard GreilJose-Artur PaivaJulien PoissyNathan Peiffer SmadjaDominique CostagliolaYazdan YazdanpanahFlorent WalletAmandine Gagneux-BrunonFrance MentréFlorence AderCharles BurdetJeremie GuedjMaude Bouscambert-Duchamp

Published in: The Journal of antimicrobial chemotherapy (2022)

Remdesivir halved viral production, leading to a median reduction of 0.7 days in the time to viral clearance compared with SoC. The efficacy was larger in patients with high viral load at randomization.

Keyphrases

sars cov
open label
phase iii
phase ii
clinical trial
study protocol
coronavirus disease
double blind
small molecule
respiratory syndrome coronavirus
placebo controlled
phase ii study
high throughput